In addition, administration of allopurinol and subsequent XO inhibition prevent muscular atrophy by inhibiting the p38 MAPK-atrogin-1 pathway and may have beneficial clinical effects, such as resistance against muscular atrophy in patients with permanent immobilization, sarcopenia, or cachexia [104, 105]. Here, FBXO32 is linked to muscular atrophy.